Repare Therapeutics (RPTX) 주식
헬스케어 부문 기업. 10월 2026 기준 Repare Therapeutics의 주가, 사업 개요, 알아두어야 할 핵심 정보를 정리했습니다.
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
≈
